Trends, predictors, and outcomes of transcatheter aortic valve implantation in patients with bicuspid aortic valve related disease: Insights from the Nationwide Inpatient Sample and Nationwide Readmission Database
Open Access
- 2 October 2022
- journal article
- research article
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 100 (6) , 1119-1131
Abstract
Background: Transcatheter aortic valve implantation (TAVI) has increasingly been utilized in patients with bicuspid aortic valve (BAV) related aortic stenosis (AS) with insufficient large‐scale data on its safety.Methods: The Nationwide Inpatient Sample and Nationwide Readmission Database (2011–2018) were queried to identify patients undergoing TAVI for BAV versus trileaflet aortic valve (TAV) associated AS. The in‐hospital, 30‐ and 180‐day odds of outcomes were assessed using a propensity‐matched analysis (PSM) to calculate adjusted odds ratios (aOR) with its 95% confidence interval (CI).Results: A total of 216,723 TAVI (TAV: 214,050 and BAV: 2,673) crude and 5,347 matched population (TAV: 2,674 and BAV: 2,673) was included in the final analysis. At index admission, the adjusted odds of in‐hospital mortality (aOR: 1.57, 95% CI: 0.67–3.66), stroke (aOR: 0.77, 95% CI: 0.38–1.57), cardiac tamponade (aOR: 0.75, 95% CI: 0.17–3.36), vascular complications (aOR: 0.33, 95% CI: 0.09–1.22), cardiogenic shock (aOR: 1.77, 95% CI: 0.93–3.38), paravalvular leak (aOR: 0.55, 95% CI: 0.26–1.14), need for mechanical circulatory support device, and permanent pacemaker implantation (PPM) (aOR: 1.02, 95% CI: 0.69–1.52) were not significantly different between TAVI for BAV versus TAV. At 30‐ and 180‐day follow‐up duration, the risk of stroke and major postprocedural complications remained similar, except that TAVI in BAV had a higher incidence of PPM implantation compared with TAV. The yearly trend showed an increase in the utilization of TAVI for both TAV and BAV and a steady decline in the overall annual rate of in‐hospital complications.Conclusion: TAVI utilization in patients with BAV has increased over the recent years. The relative odds of in‐hospital mortality, and all other major complications, were similar between patients undergoing TAVI for BAV‐ and TAV‐related AS.Keywords
This publication has 19 references indexed in Scilit:
- Adherence to Methodological Standards in Research Using the National Inpatient SampleJAMA, 2017
- Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve StenosisJACC, 2017
- Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk PatientsNew England Journal of Medicine, 2016
- Bicuspid Aortic Valve StenosisJACC: Cardiovascular Interventions, 2016
- Transcatheter Aortic Valve Implantation (TAVI) in Patients With Bicuspid Aortic Valve Stenosis – Systematic Review and Meta-AnalysisHeart, Lung and Circulation, 2015
- A prospective randomized evaluation of the TriGuard™ HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trialEuropean Heart Journal, 2015
- Transcatheter Aortic Valve Replacement in Bicuspid Aortic Valve DiseaseJACC, 2014
- Comparison of One- and 12-Month Outcomes of Transcatheter Aortic Valve Replacement in Patients With Severely Stenotic Bicuspid Versus Tricuspid Aortic Valves (Results from a Multicenter Registry)The American Journal of Cardiology, 2014
- Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk PatientsNew England Journal of Medicine, 2011
- Frequency by Decades of Unicuspid, Bicuspid, and Tricuspid Aortic Valves in Adults Having Isolated Aortic Valve Replacement for Aortic Stenosis, With or Without Associated Aortic RegurgitationCirculation, 2005